Distinct Natural Killer Cells in HIV-Exposed Seronegative Subjects With Effector Cytotoxic CD56(dim) and CD56(bright) Cells and Memory-Like CD57(+)NKG2C(+)CD56(dim) Cells

Imagem de Miniatura
Arquivos
art_LIMA_Distinct_Natural_Killer_Cells_in_HIVExposed_Seronegative_Subjects_2014.PDF (516.5 KB)
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2014
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
PEREIRA, Natalli Z.
Citação
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, v.67, n.5, p.463-471, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Innate immunity, including natural killer (NK) cells, may play a significant role in maintaining natural resistance to infection in highly HIV-exposed seronegative (HESN) subjects. The differences between NK-cell subsets, regarding their activating/maturing marker expression and their memory markers, in HESN subjects are not fully defined. Methods: We have conducted an analysis of the activating/memory markers and intracellular CD107a and interferon gamma (IFN-gamma) expression in NK-cell subsets from HESN and HIV-infected and healthy subjects. Results: HESN individuals showed an increased expression of activating markers, such as NKG2D in CD56(bright) and CD56(dim) NK cells, and an increased frequency of CD56(bright)CD127(+) and fully mature CD56(dim)CD57(+) NK cells compared with HIV-infected patients and healthy control subjects. Of note, HESN individuals showed an increased frequency of memory CD56(dim)CD57(+) NK cells, and this is known to be expanded on cytomegalovirus infection, as evidenced by their high rate of cytomegalovirus seropositivity. Simultaneous expression of the CD94, NKG2A, NKG2C, and NKG2D receptors on CD56(bright) NK cells was detected in HESN subjects, whereas in the HIV-1 group, the expression of these 4 receptors was enhanced in CD56(dim) NK cells. It was also found that CD56(bright) and CD56(dim) NK cells in HESN subjects showed increased CD107a and/or IFN-g expression. Conclusions: The NK cells from HESN individuals presented a unique activation profile, with increased expression of NKG2D, CD107a, and IFN-g and ""memory"" CD57(+) CD56(dim) NK cells. The complex network of functional NK-cell activities in HESN individuals may be exploited for long-term protection through vaccination.
Palavras-chave
NK-cell subsets, HIV-exposed seronegative, HIV-1 infection, memory NK cells, activating receptors, inhibitory receptors
URI
https://observatorio.fm.usp.br/handle/OPI/9095
Referências
  1. Alimonti JB, 2006, IMMUNOL CELL BIOL, V84, P482, DOI 10.1111/j.1440-1711.2006.01455.x
  2. Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100
  3. Boulet S, 2008, AIDS, V22, P595, DOI 10.1097/QAD.0b013e3282f56b23
  4. Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869
  5. Brunetta E, 2009, BLOOD, V114, P3822, DOI 10.1182/blood-2009-06-226332
  6. Camara M, 2010, J INFECT DIS, V201, P835, DOI 10.1086/651000
  7. Carrillo J, 2013, AIDS, V27, P1375, DOI 10.1097/QAD.0b013e32835fac08
  8. CLERICI M, 1992, J INFECT DIS, V165, P1012
  9. Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
  10. de Sorrentino AH, 2013, IMMUNOLOGY, V140, P273, DOI 10.1111/imm.12137
  11. Erickson AL, 2008, CLIN VACCINE IMMUNOL, V15, P1745, DOI 10.1128/CVI.00247-08
  12. Gasteiger G, 2013, J EXP MED, V210, P1179, DOI 10.1084/jem.20122571
  13. Guerini FR, 2011, J INFECT DIS, V203, P1235, DOI 10.1093/infdis/jir020
  14. Guma M, 2006, J INFECT DIS, V194, P38, DOI 10.1086/504719
  15. Hirbod T, 2008, AIDS, V22, P727, DOI 10.1097/QAD.0b013e3282f56b64
  16. HO M, 1990, REV INFECT DIS, V12, pS701
  17. Horton RE, 2010, J INFECT DIS, V202, pS377, DOI 10.1086/655971
  18. Kebba A, 2003, J ANTIMICROB CHEMOTH, V52, P747, DOI 10.1093/jac/dkg453
  19. Lama J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-52
  20. Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526
  21. Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108
  22. Luther C, 2011, BLOOD, V117, P4012, DOI 10.1182/blood-2010-07-298901
  23. Mantegani P, 2010, IMMUNOLOGY, V129, P220, DOI 10.1111/j.1365-2567.2009.03171.x
  24. Marras F, 2013, P NATL ACAD SCI USA, V110, P11970, DOI 10.1073/pnas.1302090110
  25. Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035
  26. Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100
  27. Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
  28. Mela CM, 2007, J INFECT DIS, V195, P158, DOI 10.1086/509811
  29. Mela CM, 2007, J INFECT DIS, V195, P159
  30. Miyazawa M, 2009, AIDS, V23, P161, DOI 10.1097/QAD.0b013e3283196a80
  31. Monsivais-Urenda A, 2010, EUR J IMMUNOL, V40, P1418, DOI 10.1002/eji.200939898
  32. Montoya CJ, 2006, CLIN IMMUNOL, V120, P138, DOI 10.1016/j.clim.2006.02.008
  33. Nattermann J, 2005, ANTIVIR THER, V10, P95
  34. Park YP, 2011, BLOOD, V118, P3019, DOI 10.1182/blood-2011-04-346825
  35. PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133
  36. Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
  37. Restrepo C, 2011, AIDS REV, V13, P30
  38. Scott-Algara D, 2003, J IMMUNOL, V171, P5663
  39. Shacklett Barbara L, 2006, Curr HIV/AIDS Rep, V3, P26, DOI 10.1007/s11904-006-0005-2
  40. Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665
  41. Sun JC, 2011, J IMMUNOL, V186, P1891, DOI 10.4049/jimmunol.1003035
  42. Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409
  43. Tomescu C, 2007, J IMMUNOL, V179, P2097
  44. Tomescu C, 2010, AIDS, V24, P2151, DOI 10.1097/QAD.0b013e32833dfc20

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03